Drug recall · November 10, 2021
Cubicin recall
Why: Presence of Particulate Matter: Identified as Glass Particles
Class I: a reasonable chance the product could cause serious harm or death.
The recall
- Product
Cubicin (daptomycin for injection), 500 mg per vial, Single-dose vial, Rx only. Manuf. for: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ 08889, USA. Manuf. by: Baxter Pharmaceuticals LLC., Bloomington, IN 47403, USA, NDC: 67919-011-01
- Lots / codes
Lot #: 934778, Exp. Date Jun 2022
- Quantity
- 76,163 vials
- Company
- Merck Sharp & Dohme Corp, Whitehouse Station, NJ
- Distribution
- Nationwide within the United States
- Initiated
- October 19, 2021 · Voluntary: Firm initiated
- Classified
- November 3, 2021
- Reported
- November 10, 2021
- Ended
- July 25, 2023
- How notified
- Press Release
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Daptomycin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.